Myriad Genetics, Inc.
MYGNHIGH VELOCITYFILING INTENSITYMyriad Genetics, Inc. reads as an High Velocity (composite 70/100); Consistent Strategic Buyer deploying $69M across 2 disclosed transactions, running flat vs the prior cycle · primary market Life Sciences.
Lens
Disclosed M&A capital (2023–2025)
$69M
vs $57M in 2020–2022
Disclosed transactions
2
2/3 active fiscal years in window
Buyer archetype
Consistent Strategic Buyer
Meaningful spend appears across repeat years.
Composite score
70
High Velocity dominates · Filing Intensity
Behavioral posture, nine reads.
Each index scores the issuer 0–100 against an EDGAR-anchored definition. Scores ≥ threshold elevate the issuer into the index's constituent set; the dominant index drives the masthead label.
Active Acquirer
Companies actively deploying disclosed capital into M&A
- $1.4B disclosed buyer spend
Buyer Cadence
Buyer-side companies with recent filing activity
- Filed within 34d
- 260 8-Ks
Target Probability
Issuers showing target-side patterns from filings
- 2 activism filings
Spin/Carve
Issuers showing spin-off, carve-out, or sum-of-parts posture
- 2 activism filings
Pressure Watch
Issuers facing activism, governance, or control pressure
- 2 activism filings
- Latest activism 29y ago; heavily discounted
Distress Watch
Issuers showing financial-distress filing patterns
- 2 activism filings
Restatement Risk
Issuers with accounting-integrity flags from filings
Capital Velocity
DominantIssuers with the highest filing-activity intensity
- 260 8-Ks
- 5 form types
Quiet Power
Large issuers with low signal volume and clean disclosure cadence
- Enterprise value $492M
- 10-Q 34d ago
- 2 active signals
Capital cadence.
Ten-year disclosed M&A activity. Bars show spend ($MM); ticks show recorded transaction count. Disclosure tier annotated where v6 audited corpus carries an entry.
Disclosed spend $MM Disclosed transactions (right axis)Peak spend year: $409M · Peak count: 2
| FY | Disclosed buys | Disclosed spend | Avg ticket | Audited tier |
|---|---|---|---|---|
| 2025 | N/A | N/A | N/A | N/A |
| 2024 | 1 | N/A | N/A | N/A |
| 2023 | 1 | $69M | $69M | N/A |
| 2022 | 1 | $57M | $57M | N/A |
| 2021 | N/A | N/A | N/A | N/A |
| 2020 | N/A | N/A | N/A | N/A |
Strategy posture.
The buyer's playbook in terms of strategic archetype: what each disclosed move says about how they're deploying capital.
Archetype mix
- Technology Acquisition25%
- Geographic Expansion25%
- Bolt On25%
- Talent Acquisition25%
Strategy keywords
Terms recurring across recent 10-K acquisition disclosures.
- technology_acquisition
- geographic_expansion
- bolt_on
- talent_acquisition
Filing language.
Direct excerpts from acquisition disclosures and strategy sections: the verbs the buyer chose, in the filings they signed.
“In May 2016, we completed the acquisition of Sividon Diagnostics GmbH (“Sividon”), a leading breast cancer prognostic company, for $39.0 million upfront with the potential for €15.0 million ($16.7 million converted at the June 30, 2016 period end exchange rate) in additional performance-based milestones.”
“we intend to continue to pursue growth through the acquisition of technology, assets or other businesses that may enable us to enhance our technologies and capabilities, expand our geographic market, add experienced management personnel and increase our test offerings.”
“The Clinic will allow us to directly negotiate reimbursement with government and private insurance providers for our tests in the German market and collaborate with hospitals and physician groups.”
“In February 2014, we completed the acquisition of privately-held Crescendo Bioscience, Inc. (“Crescendo”) for $270 million in cash”
“We believe the acquisition of the Clinic should facilitate our penetration into the German molecular diagnostic market.”
Market context.
Where this issuer sits inside its SE-Cluster rollup wedge, with disclosed-spend rank plus trading comparables against the public peer set.
Primary market
Life Sciences
- Market spend (2023–2025)
- $68.3B
- Market spend (2020–2022)
- $107.5B
- Recent vs prior
- −36%
- Issuer rank in market
- N/A
- Share of market capital
- 0.0%
Valuation positioning
MYGN trades at a -17.3-turn discount to the Life Sciences peer median of 16.1×.
- EV / Revenue
- 0.6×
- Net debt / EBITDA
- N/A
- Peer median EV / EBITDA
- 16.1×
Trading comparables
FMP market data · 2026-05-10
| Company | EV / EBITDA | EV / Rev | Net debt / EBITDA | Revenue | M&A 2023–2025 |
|---|---|---|---|---|---|
| 19.1× | 4.7× | -0.0× | $45.2B | $10.8B | |
| 18.8× | 4.3× | -0.3× | $20.6B | $8B | |
| 13.3× | 3.5× | -0.1× | $35.5B | $2.2B | |
| 13.1× | 1.9× | -0.2× | $14.1B | $2.1B |
Trading multiples from FMP market data; disclosed M&A spend from the SE-Cluster EDGAR 10-K corpus. Peer set = top disclosed buyers in Life Sciences. Bars scaled to the highest EV/EBITDA in the set.
Target landscape.
Public-issuer targets that fit this buyer's archetype and target categories from filing-derived signal. Scores reflect cross-signal fit; reasons cite the EDGAR-anchored facts that drove the match.
No qualifying public-issuer targets surfaced from the current signal mix.
Stated target categories
No target categories enumerated in the audited corpus for this issuer.
Filing activity & signal stream.
Filing cadence and event-driven signals visible on EDGAR. The signal stream below is curated from restatement / spin-carve / activism categories, providing context for any near-term call.
Filing cadence
- 10-K (annual)312026-02-24
- 10-Q (quarterly)902026-05-06
- 8-K (event)2602026-05-05
- Proxy / DEF 14A542026-04-14
- Activism (13D / DFAN / PREC)21997-09-18
Signals on file
- elevated
Activism on file
1997-09-182 activist filings on file (13D, DFAN14A, PREC14A series).
- info
Signal
Serial acquisition history
- info
Signal
10-K strategy themes
Audited corpus.
No audited record on file for this CIK in the current v6 corpus.
This issuer has not been extracted into the v6 audited acquirer corpus yet. The brief above pulls from ranking-level aggregates and issuer-index signal only.